What are the IDSA vaccination recommendations for the prevention of herpes zoster (shingles)?

Updated: Jan 25, 2019
  • Author: Camila K Janniger, MD; Chief Editor: Dirk M Elston, MD  more...
  • Print
Answer

The 2013 Infectious Disease Society of America (IDSA) clinical practice evidence-based guidelines for vaccination of immunocompromised patients includes the following recommendations for the vaccine [136] :

  • The zoster vaccine should be given to patients 60 years and older if it can be administered 4 weeks or more before beginning highly immunosuppressive therapy (strong, low).

  • The zoster vaccine should be given to patients aged 60 years and older who are receiving therapy considered to induce a low level of immunosuppression (strong, low).

  • The zoster vaccine is not recommended for highly immunocompromised patients (strong, very low).

The IDSA differs from the CDC ACIP in recommending that the zoster vaccine should be considered for patients with a history of varicella or zoster infection or who are varicella–zoster virus seropositive with no previous doses, aged 50-59 years, if it can be administered 4 weeks or more before beginning immunosuppressive therapy (weak, low).


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!